Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy

• Novo Nordisk shares are experiencing downward pressure. What’s pulling NVO shares down?The approval comes via the Commissioner's National Priority Voucher (CNPV) expedited program.The newly approved Wegovy HD (semaglutide) injection 7.2 mg is for patients who have already tolerated the currently approved 2.4 mg dose and require additional weight reduction.The therapy is intended to be used alongside a reduced-calorie diet and increased physical activity.Clinical Data From STEP UP Trial Supports ApprovalT ...